In most settings, children and adults are at equal risk of developing multidrug resistant (MDR) or rifampicin resistant (RR) tuberculosis (TB), but there are important gaps in data that limit this understanding, according to a study that was recently published in the European Respiratory Journal.

Nearly 5000 people virtually joined the official UN General Assembly side-event: "Progress and multisectoral action towards achieving global targets to end TB" co-organized by the World Health Organization (WHO) and the Russian Federation on 23 September. Held on the sidelines of the 75th UN General Assembly, the event brought together a distinguished line-up of speakers spanning WHO and UN leadership, health ministers, partners and civil society.

Despite the progress made over the last decade, TB remains the leading infectious killer disease worldwide, said Health Minister Harsh Vardhan.

In a retrospective Kaiser Permanente study, people who recovered from active tuberculosis had a higher long-term risk of death from any cause than similar patients who never had active tuberculosis.

On September 2nd and 3rd, Treatment Action Group (TAG) held a webinar series, “Demanding a Higher Standard of TB Care: New Tools, New Challenges, New Approaches to Improving TB Diagnosis and Treatment,” officially launching the two latest additions to TAG’s series of materials designed for community leaders, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis and An Activist’s Guide to Tuberculosis Diagnostic Tools.

For most people in the United States, the only awareness of tuberculosis (TB) may be the skin patch test required to work or volunteer in schools or health care facilities. But that could change during the pandemic.

Latent tuberculosis infection therapy in maintenance dialysis may be safe if combined with close follow-up and monitoring, according to results from a recently published study.

Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down

PLOS ONE publishes TAG’s rigorous, peer-reviewed calculation of investments in the development of this life-saving TB medicine.

RESIST-TB and the International Union Against Tuberculosis and Lung Disease will host a webinar on 24 September 2020 to discuss the availability of and challenges to resistance testing for second-line drugs, including the new and repurposed TB drugs.